Sanofi Pauses Recruitment in All Phase 3 Trials of Tolebrutinib
Sanofi has decided to pause recruitment globally in its Phase 3 clinical trials of tolebrutinib, an experimental BTK inhibitor, based on recommendations from the independent data monitoring committee (iDMC) overseeing the trials. The company has several ongoing studies investigating tolebrutinib’s effectiveness and safety, including one testing the investigational therapy…